Dalnicastobart

达尼苏拜单抗

Report date: 2026/05/20 20:02:01

Base Information

Drug NameDalnicastobart
Drug Alias NameLVGN7409LVGN-7409
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulantsTumor necrosis factor receptor superfamily member 5 agonists +[5] 
TargetsTumor necrosis factor receptor superfamily member 5
Therapy Area/IndicationsUveal melanomaSolid tumoursNeoplasm Metastasis +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesLyvgen Biopharma(HK)Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesLyvgen Biopharma(HK)LtdLyvgen Biopharma (Suzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsUveal melanomaSolid tumoursNeoplasm Metastasis +[11] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A